Ryan Savitz

CFO Ryan Savitz sells 31,249 shares for $3,157,150.86 via scheduled 10b5-1 plan; retains 68,751 options.

Ryan Savitz, EVP, CFO & CBO, executed 3 separate sales on 2026-07-09 totaling 31,249 shares for $3,157,150.86 at a blended average price of $101.03, reducing his non-derivative holdings to zero while retaining 68,751 shares via stock options. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-12-30, meaning execution is scheduled rather than discretionary. The stock currently trades at $98.64, a 3.6% discount from its 52-week high of $102.33, and has risen 20.2% over the past 30 days and 3.9% over 90 days. Context matters: DNTH reported quarterly revenue of $396,000.00 and a net loss of $-40,834,000.00, with annual revenue declining 67.4% year-over-year, placing the company in a distressed financial position despite its $5.4B market cap. His prior sales at this ticker (5 trades between March and April 2026) showed 30-day returns ranging from -3.5% to +11.3%, with his cross-ticker track record displaying an average 90-day return of +18.7% following sales.

CFO Ryan Savitz sold 8,224 shares of DNTH at $89.84, fully exiting position via pre-arranged 10b5-1 plan adopted 2025-12-30.

Savitz, serving as EVP, CFO & CBO, sold 8,224 shares for a total value of $738,844.16, reducing his holdings from 8,224 shares to 0 shares. This represents a complete exit from his equity stake in Dianthus Therapeutics. The sale was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-12-30, meaning the transaction followed a scheduled formula established in advance rather than a discretionary decision at the time of sale. Complete position liquidations by senior financial officers warrant disclosure review, though the plan-based nature indicates the timing and volume were predetermined rather than reactive to current conditions.

CFO Ryan Savitz sold all 114,367 shares via 8 separate transactions on 2026-03-31 for $9,492,595.50 under 10b5-1 plan

Ryan Savitz, EVP, CFO & CBO, executed 8 separate sales totaling 114,367 shares for $9,492,595.50 on 2026-03-31 through a pre-arranged 10b5-1 trading plan adopted on 2025-12-30. The complete liquidation—from 114,367 shares to 0 shares post-transaction—represents a -100.0% reduction in his holdings at the company. Transaction prices ranged from $78.33 to $85.54 across the sales, with a blended average price of $83.00. Because this activity is part of a scheduled 10b5-1 plan rather than discretionary trading, the transaction reflects a predetermined execution rather than a market-responsive decision by the CFO.

CFO Savitz Ryan sold 20,000 shares of DNTH at $45.18 (total $903,600) via pre-arranged 10b5-1 plan; reduced to zero holdings.

Savitz Ryan, serving as CFO & CBO, executed a complete liquidation of his 20,000 shares (-100.0% of pre-transaction holdings) under a pre-arranged 10b5-1 trading plan adopted on 2025-03-31. The transaction was scheduled, not discretionary, meaning it was locked in months in advance and reflects no real-time judgment about current stock levels. The sale reduced his post-transaction holdings to 0 shares, eliminating his direct equity stake in the company. While complete insider liquidations warrant attention for potential signaling, the 10b5-1 plan structure removes timing-based inference—the sale date and price were predetermined and legally divorced from current sentiment or knowledge.

CFO Ryan Savitz sells 20,000 shares ($700,000) under 10b5-1 plan; position completely liquidated

Ryan Savitz, CFO & CBO, sold 20,000 shares at $35.00 on 2025-09-09 for a total value of $700,000, reducing his holdings from 20,000 shares to 0 shares—a complete liquidation of his position. This transaction was executed under a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the sale was scheduled and automatic rather than a discretionary trade made at Savitz's real-time judgment. The complete exit of a CFO's holdings warrants investor attention as a data point, though the structured nature of the plan limits what can be inferred about near-term conviction. The absence of any remaining position means Savitz has no further financial alignment with Dianthus shareholders from equity ownership.